Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

Neurology

Volumn 71, Issue 18, 2008, Pages 1390-1395

  Birnbaum, G ^a   Cree, B ^b   Altafullah, I ^a   Zinser, M ^d   Reder, A T ^c  

^a Minneapolis Clinic of Neurology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA1A INTERFERON; GADOLINIUM; GLUCOCORTICOID; PLACEBO; BETA INTERFERON; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR; PYRROLE DERIVATIVE;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HUMAN; LABORATORY TEST; MALE; MULTIPLE SCLEROSIS; MYALGIA; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; SIDE EFFECT; WEAKNESS; ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL;

ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROLOGIC EXAMINATION; PYRROLES; SURVIVAL ANALYSIS;

EID: 56549086423     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000319698.40024.1c     Document Type: Article

References (42)

1. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating- remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients: Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995;1:118-135.
3. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arna-son BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-18.
4. de Andres C, Aristimuno C, de Las Heras V, et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007;182:204-211.
5. Floris S, Ruuls SR, Wierinckx A, et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002;127:69-79.
6. Hu X, Ho HH, Lou O, Hidaka C, Ivashkiv LB. Homeo-static role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction. J Immunol 2005;175:131-138.
7. Liu Z, Pelfrey CM, Cotleur A, Lee JC, Rudick RA. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001;112:153-162.
8. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-689.
9. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003;197:725-733.
10. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
11. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guide- lines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
14. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-153.
15. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-895.
16. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001;131:41-46.
17. Sadeghi MM, Tiglio A, Sadigh K, et al. Inhibition of interferon-gamma- mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001;71:1262-1268.
18. Wagner AH, Schwabe O, Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 2002; 136:143-149.
19. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989;11:863-869.
20. Azuma RW, Suzuki J, Ogawa M, et al. HMG-CoA reduc-tase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 2004;64:412-420.
21. Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003;17:905-907.
22. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687-692.
23. Nath N, Giri S, Prasad R, Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reduc-tase inhibitor for multiple sclerosis therapy. J Immunol 2004;172:1273-1286.
24. Kuipers HF, Rappert AA, Mommaas AM, et al. Simvasta-tin affects cell motility and actin cytoskeleton distribution of microglia. Glia 2006;53:115-123.
25. Montero MT, Hernandez O, Suarez Y, et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000; 153:303-313.
26. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J 2005;19:1407-1421.
27. Danesh FR, Anel RL, Zeng L, Lomasney J, Sahai A, Kanwar YS. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) 2003;51: 139-148.
28. Andersson M, Low P, Bakhiet M. Lovastatin inhibits interferon-gamma- induced Trypanosoma brucei brucei proliferation: evidence for mevalonate pathway involvement. J Interferon Cytokine Res 1996;16:435-439.
29. Chung HK, Lee IK, Kang H, et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002;34:451-461.
30. Huang KC, Chen CW, Chen JC, Lin WW. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci 2003;10: 396-405.
31. Dhawan N, Reder A. Statins block interferon signaling in human immune cells: potential loss of the therapeutic effect of IFN-beta in multiple sclerosis. Neurology 2007;68: A364.
32. Kieseier BC, Archelos JJ, Hartung HP. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 2004;61:929-932.
33. Takahashi HK, Mori S, Iwagaki H, et al. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 2005;77:400-407.
34. Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors: report of 4 cases and review of the literature. Medicine (Baltimore) 1998;77:378-383.
35. Markovic-Plese S, Speer D, Jin J, et al. Statin and intramuscular interferon beta-1a combination therapy is safe and well tolerated in patients with clinically isolated syndrome suggestive of multiple sclerosis, a pilot study. Mult Scler 2007;13:S270.
36. Rudick R, Pace A, Panzara M, et al. Effects of statins on intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis. Mult Scler 2007;13:S57.
37. Sørensen PS, Frederiksen JL, Lycke J, Sellebjerg F. Does simvastatin antagonize the effect of interferon beta? Interim safety analysis of the ongoing SIMCOMBIN study. Mult Scler 2007;13:S25.
38. Orefice G, Quarantelli M, Salvatore P, et al. An open label, randomized clinical trial of atorvastatin in combination with interferon beta-1a in active MS patients; 12 months results. Mult Scler 2007;13:S56.
39. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
40. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophi-licities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) re-ductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991;80:830-834.
41. Davidson MH, Robinson JG. Lipid-lowering effects of statins: a comparative review. Exp Opin Pharmacother 2006;7:1701-1714.
42. Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004;47:73-104.